Goldman Sachs Raises GoodRx (GDRX) Price Target, Keeps Neutral Rating

GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 12 Best American Penny Stocks to Buy Right Now. On November 6, Goldman Sachs increased its price target on GoodRx Holdings, Inc. (NASDAQ:GDRX) from $3.75 to $4 and kept a Neutral rating.

This decision came after the company reported its results for the third quarter of 2025. The research firm highlighted that GoodRx Holdings, Inc. (NASDAQ:GDRX) is working on expanding accessibility and affordability programs. The company is also engaged in talks about participating in the TrumpRx initiative.

Goldman Sachs noted that there are ongoing challenges in the industry. These include uncertainties about the Affordable Care Act marketplace subsidies and Medicaid support. The firm pointed out that GoodRx Holdings, Inc. (NASDAQ:GDRX) delivered a strong performance through its pharma manufacturer solutions in the third quarter of 2025.

Additionally, Goldman Sachs mentioned the company’s new brand campaign, which helps raise awareness of its consumer products and services. These include new subscription services that focus on hair loss and weight loss treatments.

However, the research firm cautioned that GoodRx Holdings, Inc. (NASDAQ:GDRX) could experience volatility. This risk comes from potential regulatory changes and platform launches from Washington. Consumer affordability challenges are also expected to remain an important area for investors.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is an American company that is known for its digital healthcare platform that connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make medications more affordable and accessible.

While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Stocks Under $20 to Buy According to Analysts and 12 Best Performing Stocks in the Last 3 Months.

Disclosure: None. This article is originally published at Insider Monkey.